Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

 Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

Shots:
  • Lilly to acquire Hydra, in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists
  • The focus of the acquisition is to develop treatments for chronic pain and understand TRP pathway in pain signaling, further initiate clinical trials
  • Hydra’s Transient Receptor Potential (TRP) channel program consists of group of non-selective
    cation channels indicated for the treatment of pain, inflammation and hypertension

Click here to read full press release/ article | Ref: Eli Lilly | Image:  PM Live

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post